ORINF (Orion Oyj) Moat Score: 6/10 (As of Jun. 29, 2026)


ORINF Orion Oyj ORINF
100 GF Score
Price $82.75
GF Value $82.46
! 3 Warning Signs
View Full Analysis

What is Orion Oyj Moat Score?

Orion Oyj ORINF +4.81% 100 Moat Score is 6 as of Jun. 29, 2026. GuruFocus rates ORINF with a GF Score™ of 100/100 and a GF Value™ of $82.46. The stock has 3 warning signs investors should review. Among 1,030 Drug Manufacturers companies, Orion Oyj ranks better than 97.09% on this metric.

Orion Oyj has the Moat Score of 6, which implies that the company might have Narrow Moat - Strong narrow moat, clearly distinguishable but not wide.

Orion Oyj has Narrow Moat: Orion Oyj has a strong narrow moat with a solid market position in pharmaceuticals, supported by valuable patents and a strong distribution network. However, it lacks the scale and brand dominance for a wide moat.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Orion Oyj might have Narrow Moat - Strong narrow moat, clearly distinguishable but not wide.

Orion Oyj  (OTCPK:ORINF) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Orion Oyj Moat Score Related Terms

ORINF vs LLY, JNJ, ABBV: Moat Score Comparison

For the Drug Manufacturers - General subindustry, Orion Oyj's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Orion Oyj Moat Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Orion Oyj's Moat Score distribution charts can be found below:

* The bar in red indicates where Orion Oyj's Moat Score falls into.


ORINF
100GF Score
Orion Oyj ORINF
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 6 mean?
Orion Oyj (ORINF) has a Moat Score of 6 as of Jun. 29, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Orion Oyj ranks #30 out of 1030 companies in the Drug Manufacturers industry, placing it in the top 2.9%.
Is Orion Oyj's Moat Score too high?
Orion Oyj's current Moat Score is 6. Based on the distribution chart, Orion Oyj ranks #30 out of 1030 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Orion Oyj has a GF Score™ of 100/100, reflecting its overall financial health beyond just this single metric.
How does Orion Oyj's Moat Score compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Orion Oyj ranks #30 out of 1030 companies for Moat Score. This places Orion Oyj in the top 3% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Drug Manufacturers company?
A good Moat Score depends on the Drug Manufacturers industry context. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. Orion Oyj's current Moat Score is 6. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Orion Oyj stock overvalued right now?
Orion Oyj (ORINF) has a current Moat Score of 6. The stock's GF Value™ is $82.46, compared to a current price of $82.75 — trading 0.4% above its estimated fair value. The current Moat Score is 6. Orion Oyj's overall GF Score™ is 100/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Orion Oyj (ORINF), the current Moat Score is 6 as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Orion Oyj (ORINF) Overvalued in 2026?

Based on GuruFocus' analysis, Orion Oyj stock appears to be overvalued. The current stock price of $82.75 is trading 0.4% above its estimated GF Value™ of $82.46.

Key valuation signals for ORINF:

  • Moat Score: 6
  • GF Value™: $82.46 vs. price of $82.75 (0.4% above fair value)
  • GF Score™: 100/100 with 3 warning signs

No single metric tells the full story. See the ORINF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Orion Oyj Business Description

Address Orionintie 1, Espoo, FIN, FI-02200
Orion Oyj is a globally operating Finnish pharmaceutical company that develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients. The company predominantly focuses on treatments for central nervous system disorders, oncology, and respiratory diseases. Orion's customers include specialists and general practitioners, veterinarians, pharmacies, hospitals, and laboratories. The company mainly serves Finland but also has a presence in other European countries, North America and other countries.
100GF Score

Get the complete analysis for ORINF

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$82.75
Price
$82.46
GF Value